ReviewJapanese journal of clinical oncology2016
Skin problems and EGFR-tyrosine kinase inhibitor.
Review in Japanese journal of clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Rash associated with epidermal growth factor receptor inhibitors: a systematic review and meta-analysis of 194 randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia.Cancer science · 2022Trial
- Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.The oncologist · 2020Trial
- Cutaneous adverse events associated with Rybrevant based on FDA adverse event reporting system (FAERS) database from 2021 to 2024.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Safety Profile and Tumor Response of EGFR-TKIs in Clinical Practice: A Real-World Study in Thailand.Journal of clinical medicine · 2026Article
- Role of solute carrier transporters in the biodistribution and toxicity of chemotherapeutic drugs.Pharmacological reviews · 2026Review
- Skin Epidermal Progenitor Maintenance by the SRCAP-H2A.Z Axis Downstream to Extracellular Signal-Regulated Kinase and mTOR Signaling.The Journal of investigative dermatology · 2026Article
- Global pharmacovigilance analysis of dermatologic toxicity in EGFR-TKI-treated NSCLC: a cross-database real-world study.Frontiers in pharmacology · 2026Article
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment.Clinical and translational science · 2025Review
- Complications and outcomes of radioligand therapy in patients with neuroendocrine neoplasms depending on the baseline glomerular filtration rate.European journal of nuclear medicine and molecular imaging · 2025Article
- Epidermal growth factor receptor inhibitor-related skin toxicities: a review of management and possible preventive and therapeutic approaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study Team.International journal of clinical oncology · 2025Review
- Acneiform drug eruption from pirfenidone.JAAD case reports · 2025Article
- Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition.Pharmaceutics · 2025Review
- The Role of Tyrosine Kinase in Beauty and Skincare: A Comprehensive Review.Journal of cosmetic dermatology · 2025Review
- A novel anti-HER2/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs.Investigational new drugs · 2025Article
- Rare skin adverse reactions induced by osimertinib: a case report and literature review.Frontiers in oncology · 2025Article
- Article
- Article
- Osimertinib‑induced erythromelalgia: A case report.Experimental and therapeutic medicine · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor inhibition is a good target for the treatment of lung, colon, pancreatic and head and neck cancers. Epidermal growth factor receptor-tyrosine kinase inhibitor was first approved for the treatment of advanced lung cancer in 2002. Epidermal growth factor receptor-tyrosine kinase inhibitor plays an essential role in the treatment of cancer, especially for patients harbouring epidermal growth factor receptor activating mutation. Hence, skin toxicity is the most concerning issue for the epidermal growth factor receptor-tyrosine kinase inhibitor treatment. Skin toxicity is bothersome and sometimes affects the quality of life and treatment compliance. Thus, it is important for physicians to understand the background and how to manage epidermal growth factor receptor-tyrosine kinase inhibitor-associated skin toxicity. Here, the author reviewed the mechanism and upfront preventive and reactive treatments for epidermal growth factor receptor inhibitor-associated skin toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.